One Genomics is at the forefront of genome editing technology with its innovative Safeguard sgRNA platform, which enhances the safety, precision, and efficacy of the CRISPR gene editing system. This patented technology allows for fine-tuning of genome editing processes, significantly improving the efficiency of homology-directed repair (HDR) by seven times while prioritizing safety by reducing adverse effects such as p53 activation and cytotoxicity. The platform boasts an impressive 3000-fold increase in precision, minimizing off-target effects and ensuring that gene editing is conducted with high accuracy and control. This advancement positions One Genomics as a leader in developing transformative therapies for genetic diseases, cancer, and longevity.

The company actively seeks partnerships and collaborations with prestigious institutions such as Stanford University, Harvard Medical School, and several Japanese universities to further research and develop gene therapies utilizing their Safeguard sgRNA technology. By fostering these joint research initiatives, One Genomics aims to leverage its groundbreaking technology to create innovative treatments that address a wide range of genetic disorders and enhance overall health outcomes. Their commitment to safety and precision in genome editing underscores their dedication to advancing the field of genomics and improving patient care.

United States

One Genomics is a CRISPR based gene editing company focused on developing transformative gene editing tools and therapies using its proprietary editing technologies, allowing for precise changes to genomic DNA.

One Genomics

Company Details